FORMATION OF FOCI OF P53 BOUND PROTEIN 1 IN THYROID TUMORS: ACTIVATION OF GENETIC INSTABILITY DURING THYROID CARCINOGENESIS. LITERATURE REVIEW
Introduction: In our days big successes have been reached in studying of molecular–cellular mechanisms in carcinogenesis, establishing the role of oncogens and antioncogens in the development of tumors with various localization, including thyroid cancer. The vast majority of benign and malignant tumors of the thyroid gland develops from the follicular epithelium, which have different degrees of differentiation, different morphogenetic and biochemical features, clinical course and prognosis. Objective: to conduct a search for scientific information on the activation of genetic instability in the course of thyroid carcinogenesis. Search strategy: The search for sources was carried out on the basis of Pubmed (https://www.ncbi.nlm.nih.gov/pubmed/), using the specialized search engine Google Scholar and in the electronic scientific library CyberLeninka. Search depth was 13 years: from 2004 till 2017. The following key queries were used: adenoma, oncocytes, expression, thyroid, 53BP1. Inclusion criteria: publications that are in full-text access; articles in English, Russian, studies conducted in the near and far abroad. Exclusion criteria: articles describing isolated cases; articles published before 1991; summary of reports. A total of 1533 sources were found, of which 75 were selected for further analysis. Search results: Analysis of the literature data showed that follicular adenoma (FA) is the most common form of thyroid tumors and occurs in 4-7% of the adult population [12]. FA develops both in the intact organ and on the background of any pathological changes, especially nodular goiter and chronic autoimmune thyroiditis [49]. One of the most difficult aspects of studying Hurthle’s cell tumors is to determine whether the lesion is benign or malignant. Initially, it was believed that Hurthle's cell is the result of senile changes in the thyroid follicular-epithelial cell, because Hurthle’s cells are more common in the elderly. Most likely, this assumption is not far from the truth. Hurthle’s cells are less active than follicular cells, their production of thyroglobulin is limited. At the same time, they demonstrate a high level of oxidative enzymes [41]. Numerous studies have shown that all forms of thyroid neoplasia are likely to have an oncocytic component. In particular, Trovisco V et al. (2004) it was found that BRAF FV600E mutations are found in many common types of PTCs and in oncocyte variants of PTC, while this anomaly is not detected in oncocytic follicular variants of papillary cancer [65,66]. Discussion of the search results: For prognosis improving of oncocyte follicular adenomas of the thyroid glands with traditional methods, it is necessary to include molecular genetics methods, create possibilities to diagnose diseases at the level of altered DNA structure, allow to determine localization of hereditary disorders. Molecular genetic methods can identify mutations which connected associated even with the replacement of one / single basis.
Zhanna U. Коzykenova1, http://orcid.org/0000-0001-7420-2279 Bekbolat А.Zhetpisbaev1, http://orcid.org/0000-0002-8903-8560 Galiya Т. Nurmadieva, http://orcid.org/0000-0001-8720-349Х Nailya М. Urazalina, Laura А. Ibraqimova 1 The Department of Pathological physiology named after T.A. Nazarova, Semey Medical University, Semey, Republic of Kazakhstan
1 Алубаев А.С., Кательницкий И.И., Лукьянов С.В. Солитарная фолликулярная неоплазия щитовидной железы: оптимизация диагностики и хирургического лечения // Кубанский научный медицинский вестник. 2013. №4 (139). С.10-13. 2 Аргунов В.А., Труфанов А.С., Фарафонов В.Б., Лоскутова К.С., Горохова Н.Н., Колесникова Т.Н., Шведова А.З., Семенов Н.М. Гистологическая характеристика папиллярного рака щитовидной железы // Сибирский онкологический журнал. 2006. №3. С.84-85. 3 Аристархов В.Г., Донюков А.И., Пузин Д.А., Аристархов Р.В. Особенности морфологии многоузлового зоба // Современные аспекты хирургической эндокринологии. Саранск, 2007. С.11-12. 4 Битарова И.К., Ворохобина Н.В., Кусова А.Р. Особенности распространения и структуры тиреоидной патологии на территории города с неблагоприятной экологической обстановкой и дефицитом йода в биосфере // Российский семейный врач. 2006. №4. С. 38-40. 5 Бомаш Н.Ю. Морфологическая диагностика заболеваний щитовидной железы. М.: Медицина, 1981. С. 176. 6 Валдина Е.А. Заболевания щитовидной железы. СПб.: Питер, 2006.С. 89-90. 7 Волченко Н.Н., Славнова Е.Н. Цитологические критерии диагностики рака щитовидной железы // Сибирский онкологический журнал. 2006. №3.С.5-7. 8 Ворохобина Н.В., Кузьмина В.А., Крючкова З.В. Распространенность заболеваний щитовидной железы у лиц молодого возраста среди жителей Санкт-Петербурга // Российский семейный врач. 2006. №1.С. 48. 9 Гольбрайх В.А., Кухтенко Ю.В., Голуб В.А., Косивцов О.А., Бубликов А.Е. Узловой зоб: современные подходы к диагностике и лечению // Вестник ВолГМУ. 2010. №1 (33).С.111-115. 10 Двинских Н.Ю., Абросимов А.Ю. Аденома или рак щитовидной железы? (иммуноморфологическое исследование потенциала злокачественности инкапсулированных опухолей фолликуляр-ного строения) // Рак щитовидной железы. Современные принципы диагностики и лечения. СПб., 2009. С.45-48. 11 Европейский консенсунс по диагностике и лечению дифференцированного рака щитовидной железы из фолликулярного эпителия // Клиническая и экспериментальная тиреоидология. 2006. Т. 2, №3. С.13. 12 Зайратьянц О.В., Фадеев В.В., Белоцерковская М.М. и др. Нозологическая структура узловых образований щитовидной железы по данным аутопсий // Архив патол. 2004. Т. 66, №6.С. 24-28. 13 Казанцева И.А., Павлова Т.В., Гуревич Л.Е., Корсакова Н.А. Аденомы щитовидной железы: состояние проблемы и собственные наблюдения // Современные аспекты хирургической эндокринологии. Ижевск, 2009. С.91-93. 14 Козыкенова Ж.У., Жагипарова Ж.К. и др. Геномная нестабильность при онкоцитарной фолликулярной аденоме щитовидной железы // Астана медициналық журналы. 2017. №3. С.146-150. 15 Козыкенова Ж.У., Жетписбаев Б.А. и др. Онкоцитарный вариант фолликулярных опухолей щитовидной железы (Обзор литературы) // Журнал Medicine. Aлматы, 2016. №11 (173). С. 60-64. 16 Лужанская Е.М. Дифференциальная морфологическая диагностика фолликулярной аденомы щитовидной железы и узлового зоба // Вятский медицинский вестник. 2009. №1. С. 76. 17 Лужанская Е.М. Сравнительная морфологическая характеристика нетоксической фолликулярной аденомы щитовидной железы и аденоматоидной гиперплазии при узловом зобе // Пермский медицинский журнал. 2010. №2. С.97-102. 18 МКБ-10:Международная статистическая классификация болезней и проблем, связанных со здоровьем:10-й пересмотр: Том 1: Часть 2. С.12. 19 Орлинская Н.Ю. Дооперационная морфологическая диагностика узловых образований щитовидной железы (лекция) // Медицинский альманах. 2014. №5(35). С. 138-141. 20 Орлинская Н.Ю., Хмельницкая Н.М. Патология щитовидной железы у жителей Нижегородской области по данным операционного материала // Медицинский альманах. 2011. №4. С. 160–161. 21 Павлова Т.В., Павлов И.А. Клинико-морфологические аспекты рака щитовидной железы // Научные ведомости: Фармация. 2011. №4. С. 13–20. 22 Петров В.Г., Нелаева А.А., Якимов С.А., Машкин А.М., Малинин Д.И. Фолликулярная аденома щитовидной железы // Сибирский онкологический журнал. 2006. №1.С.80-81. 23 Пинский С.Б., Белобородов В.А. Аденома щитовидной железы // Сиб. мед. журнал. Иркутск, 2010. №3.С.73-77. 24 Тимофеева Л.А., Алешина Т. Н., Семенов В.Д. Анализ возможных причин автономной аденомы щитовидной железы // Вестник ЧГУ. 2014. №2. С. 378-384. 25 Трошина Е.А., Юшков П.В., Мазурина Н.В., Егорычева Е.К., Абесадзе И.А. Фолликулярная неоплазия щитовидной железы // Проблемы эндокринологии. 2006. №1. С. 22-25. 26 Хмельницкий О.К. Цитологическая и гистологическая диагностика заболеваний щитовидной железы. СПб.: СОТИС, 2002. 288 с. 27 Чумаков П.М. Белок р53 и его универсальные функции в многоклеточном организме // Успехи биологической химии. 2007. Т. 47. С. 3-52. 28 Чуруксаева О.Н., Коломиец Л.А., Савенкова О.В., Недосеков В.В. Иммуногистохимические факторы в прогнозе местно-распространенного рака шейки матки // Опухоли женской репродуктивной системы. 2012. №3-4. С.126-133. 29 Шабалина Е.А., Моргунова Т.Б., Орлова С.В., Фадеев В.В. Селен и щитовидная железа // КЭТ. 2011. №2. С. 7-18. 30 Шестериков А.С. Фолликулярная неоплазия щитовидной железы (клинико-морфологические корреляции, хирургическое лечение): автореф. канд. мед. наук. СПб., 2006. С. 27. 31 Baloch Z.W., Fleisher S., LiVolsi V.A. Diagnosis of «Follicular Neoplasm»: a Gray Zone in Thyroid Fine-needle Aspiration Cytology Diagn // Cytopathol. 2002. № 26(1). Р.41- 46. 32 Baloch Z.W., LiVolsi V.A. Follicular-Patterned Lesions of the Thyroid. The Bane of the Pathologist // Am.J.Clin.Pathol. 2002. №117.Р.143-150. 33 Bronner M., LiVolsi V.A. Oxyphilic (Askenasy/Hu¨rthle cell) tumors of the thyroid: microscopic features predict biologic behavior // Surg Pathol. 1988. №1.Р. 137-150. 34 Bondeson L., Azavedo E., Bondeson A.G., Caspersson T., Ljungberg O. Nuclear DNA content and behavior of oxyphil thyroid tumors // Cancer. 1986. №58.Р.672-675. 35 Bork P., Hofmann K., Bucher P., Neuwald A.F., Altschul S.F. et al. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins // FASEB J. – 1997. - №11. - Р. 68-76. 36 Caplan R.H., Abellera R.M., Kisken W.A. Hurthle cell tumors of the thyroid gland: a clinicopathologic review and long-term follow-up // JAMA. 1984. №251. Р.3114-3117. 37 Difilippantonio M.J., Petersen S., Chen H.T., Johnson R., Jasin M., Kanaar R., Ried T., Nussenzweig A. Evidence for replicativerepair of DNAdouble-strand breaks leading to oncogen ictrans location and geneamplification // J Exp Med. 2002. №196.Р.469-480. 38 Fagin F.A., Matsuo K., Karmakar A. еt al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas // J. Clin. Invest. 1993. Vol. 91, №1. P. 179-184. 39 Grant C.S., Barr D., Goellner J.R. et al. Benign Hürthle cell tumors of the thyroid: a diagnosis to be trusted? // World J. Surg. 1988. Vol. 12. P. 488-495. 40 Har-El G., Hadar T., Segal K., Levy R., Sidi J. Hurthle cell carcinoma of the thyroid gland: a tumor of moderate malignancy // Cancer. 1986. №57.Р.1613-1617. 41 Harcourt-Webster J.N., Stott N.C. Histochemical study of oxidative and hydrolyticenzymes in the human thyroid // J. Pathol Bacteriol. 1966. Vol. 92. P. 291-302. 42 Herrmann M., Baunoch DA., Maliarik M. еt al. P53 genealterationsi n differentiated thyroid cancers // Oncol. Rep. 1995. Vol. 2. P. 741-748. 43 Hunt J.L., Tometsko M., LiVolsi VA., Swalsky P., Finkelstein SD., Barnes E.L. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid // Am J Surg Pathol.2003. №27.Р.1559-1564. 44 Ito T., Seyama T., Mizuno T. et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland // Cancer Res. 1992. Vol. 52, №5. P. 1369-1371. 45 Joo W.S., Jeffrey P.D., Cantor S.B., Finnin M.S., Livingston D.M. et al. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCTstructure // Genes Dev. 2002. - №16. Р. 583-593. 46 Jones S. N., Hancock A. R. et al. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis // Proc Natl Acad Sci. USA, 1998. № 95(26). Р.15608-12. 47 Jossart G.H., Epstein H.D., Shaver J.K. et al. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines // J. Clin. Endocrinol. Metab.1996. Vol. 81, №10. P. 3498-3504. 48 Kamb A., Gruis N.A., Weaver Feldhaus J. et al. A cell regulator potentially involved in genesis of many tumor types // Science. 1994. Vol. 264, №5157. P. 436-440. 49 Kovalev S., Marchenko N., Swendeman S., LaQuaglia M., Moll U. M. Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines // Cell Growth Differ. 1998. №9. Р. 897–903. 50 Lassmann M., Hanscheid H., Gassen D., Biko J., Meineke V. et al. In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodinetherapy of differentiated thyroid cancer // J Nucl Med. 2010. №51.Р.1318-1325. 51 Lozano G., Elledge S.J. p53 sends nucleotides to repair DNA // Nature. 2000. №404. Р.24-25. 52 Muller P.A., Vousden K.H. Mutant p53 in cancer: new functions and therapeutic opportunities // Cancer Cell. 2014. №25.Р. 304-317. 53 Moynahan M.E., Jasin M. Loss of heterozygosity in duced byachromosomal double-strandbreak // Proc Natl Acad Sci. USA, 1997. №94.Р.8988-8993. 54 Olive K.P., Politi K. Translational therapeutics in genetically engineered mouse models of cancer //Cold Spring Harb Protoc. 2014. №2.Р.131-43 // doi: 10.1101/pdb.top069997. 55 Panier S., Boulton S.J. Double-strand break repair:53BP1 comes into focus // Nat Rev Mol Cell Biol. 2014. №15. Р.7-18. 56 Pacini F., Burroni L., Ciuoli C. et al. Management of thyroid nodules: a clinicopathological, evidence_based approach // Eur. J. of Nucl. Med. and Molec. Imaging 2004. Vol. 31. P. 1443–1449. 57 Pipiras E., Coquelle A., Bieth A., Debatisse M. Interstitial deletions and intrachromosomal amplification initiated from a double-strand break targeted to a mammalian chromosome // EMBOJ. 1998. №17. Р. 325-33. 58 Rappold I., Iwabuclii K., Date Т., Chen J. Tumor suppressor p53 binding protein I (53BP1) is involved in DNA damage-signaling pathways // Journal of Cell Biology. 2001. Vol. 153, №3. P. 613-620. 59 Rinaldo C., Prodosmo A., Mancini F. et al. MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. // MolCell. 2007. №25. Р.739-50. 60 Richardson C., Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks // Nature. 2000. №405.Р. 697-700. 61 Shimizu H., Hupp T.R. Intrasteric regulation of MDM2 // Trends Biochem Sci. 2003. № 28(7). Р.346-349. 62 Shmueli A., Oren M. Mdm2: p53’slifesaver? // Mol Cell. 2007. №25.Р.794-796. 63 Schultz L.B., Chehab N.H., Malikzay A., Halazonetis T.D. p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks // J Cell Biol. 2000. №151.Р.1381-90. 64 Schwab M., Praml C., Amler L.C. Genes Chromosomes // Cancer.1996. №16. Р. 211-229. 65 Soares P., Trovisco V., Rocha A.S. et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC // Oncogene.2003. №22.Р.4578-4580. 66 Trovisco V., Vieira-Castro I., Soares P. et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma // J Pathol. 2004. №202.Р. 247-251. 67 Ward I.M., Minn K., Jorda K.G., Chen J. Accumulation of checkpoint protein 53BP1 at DNA breaks in volvesitsbinding to phosphory lated histone H2AX // J Biol Chem. 2003. №278.Р.19579-82. 68 Ward I.M., Minn K., van Deursen J., Chen J. p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice // Mol Cell Biol. 2003. №23. Р.2556-2563. 69 Wang H., Zhang X., Teng L., Legerski R.J. DNA damage checkpoint recovery and cancer development // Exp Cell Res. 2015. №334. Р. 350-358. 70 Wallace M.D., Southard T.L., Schimenti K.J., Schimenti J.C. Role of DNA damage response pathways in preventingcarcinogenesis caused by intrinsic replication stress // Oncogene. 2014. №33. Р. 3688-3695. 71 Zamzami N. P53 in apoptosis control: introduction // Zamzami N., Krotmer G.// Biochemical and Biophysical Research Communications. 2005.№331(3). P.685-687. 72 Zhu C., Mills K.D., Ferguson D.O., Lee C., Manis J., Fleming J., Gao Y., Morton C.C., Alt F.W., Banin S., Moyal L., Shieh S., et al. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations // Cell. 2002. №109.Р.811-21. 73 Zedenius J., Larsson C., Wallin G. et al. Alterations of p53 and expression of WAF1/p21 in human thyroid tumors // Thyroid. 1996. Vol.6, №1. P. 1-9. 74 Xu Y., Baltimore D. Dual roles of AT Minthecellular response to radiation and in cell growth control // Genes Dev. 1996. №10.Р.2401-10. 75 Xu Y., Yang E.M., Brugarolas J., Jacks T., Baltimore D. Involvement of p53 and p21 in cellular defects and tumorigenesis in Atm2/2 mice // MolCellBiol.1998. №18. Р.4385-4390. References: 1 Alubaev A.S., Katel'nitskii I.I., Luk'yanov S.V. Solitarnaya follikulyarnaya neoplaziya shchitovidnoi zhelezy: optimizatsiya diagnostiki i khirurgicheskogo lecheniya [Solitary follicular neoplasia of the thyroid gland: optimization of diagnosis and surgical treatment]. Kubanskii nauchnyi meditsinskii vestnik [Kuban scientific medical journal]. 2013. №4 (139). рр.10-13. [in Russian] 2 Argunov V.A., Trufanov A.S., Farafonov V.B., Loskutova K.S., Gorokhova N.N., Kolesnikova T.N., Shvedova A.Z., Semenov N.M. Gistologicheskaya kharakteristika papillyarnogo raka shchitovidnoi zhelezy. [Histological characteristics of papillary thyroid cancer]. Sibirskii onkologicheskii zhurnal. [Siberian Oncological Journal]. 2006. 3. pp.84-85. [in Russian] 3 Aristarkhov V.G., Donyukov A.I., Puzin D.A., Aristarkhov R.V. Osobennosti morfologii mnogouzlovogo zoba. Sovremennye aspekty khirurgicheskoi endokrinologii. [Features of the morphology of multinodular goiter]. [Modern aspects of surgical endocrinology]. Saransk, 2007. рр.11-12. [in Russian] 4 Bitarova I.K., Vorokhobina N.V., Kusova A.R. Osobennosti rasprostraneniya i struktury tireoidnoi patologii na territorii goroda s neblagopriyatnoi ekologicheskoi obstanovkoi i defitsitom ioda v biosphere. [Features of the distribution and structure of thyroid pathology in the city with an unfavorable environmental situation and iodine deficiency in the biosphere]. Rossiiskii semeinyi vrach [Russian family doctor]. 2006. №4. рр. 38-40. [in Russian] 5 Bomash N.Yu. Morfologicheskaya diagnostika zabolevanii shchitovidnoi zhelezy. [Morphological diagnosis of thyroid diseases]. M.: Meditsina [Medicine] 1981. р. 176. [in Russian] 6 Valdina E.A. Zabolevaniya shchitovidnoi zhelezy. [Thyroid disease]. SPb.: Piter, 2006.pp. 89-90. [in Russian] 7 Volchenko N. N., Slavnova E. N. Tsitologicheskie kriterii diagnostiki raka shchitovidnoi zhelezy. [Cytological criteria for the diagnosis of thyroid cancer]. Sibirskii onkologicheskii zhurnal [Siberian Journal of Oncology]. 2006. №3. рр.5-7. [in Russian] 8 Vorokhobina N.V., Kuz'mina V.A., Kryuchkova Z.V. Rasprostranennost' zabolevanii shchitovidnoi zhelezy u lits molodogo vozrasta sredi zhitelei Sankt-Peterburga. [The prevalence of thyroid diseases in young people among residents of St. Petersburg]. Rossiiskii semeinyi vrach [Russian family doctor]. 2006. №1.рр. 48. [in Russian] 9 Gol'braikh V.A., Kukhtenko Yu.V., Golub V.A., Kosivtsov O.A., Bublikov A. E. Uzlovoi zob: sovremennye podkhody k diagnostike i lecheniyu. [Nodular goiter: modern approaches to diagnosis and treatment]. Vestnik VolGMU [Bulletin of Volgograd State Medical University]. 2010. №1 (33).рр.111-115. [in Russian] 10 Dvinskikh N.Yu., Abrosimov A.Yu. Adenoma ili rak shchitovidnoi zhelezy? (immunomorfologicheskoe issledovanie potentsiala zlokachestvennosti inkapsulirovannykh opukholei follikulyarnogo stroeniya). Rak shchitovidnoi zhelezy. Sovremennye printsipy diagnostiki i lecheniya. [Adenoma or thyroid cancer? (immunomorphological study of the potential malignancy of encapsulated tumors of a follicular structure). Thyroid cancer. Modern principles of diagnosis and treatment]. SPb., 2009. рр.45-48. [in Russian] 11 Evropeiskii konsensuns po diagnostike i lecheniyu differentsirovannogo raka shchitovidnoi zhelezy iz follikulyarnogo epiteliya. [European Consensus on Diagnosis and Treatment of Differential Thyroid Cancer of the Follicular Epithelium]. Klinicheskaya i eksperimental'naya tireoidologiya [Clinical and Experimental Thyroidology]. 2006. T. 2, №3. рр.13. [in Russian] 12 Zairat'yants O. V., Fadeev V.V., Belotserkovskaya M.M. i dr. Nozologicheskaya struktura uzlovykh obrazovanii shchitovidnoi zhelezy po dannym autopsii [Nosological structure of thyroid nodules according to autopsies]. Patol. arkhiv [Archive patol]. 2004. T. 66, №6. рр. 24-28. [in Russian] 13 Kazantseva I.A., Pavlova T.V., Gurevich L.E., Korsakova N.A. Adenomy shchitovidnoi zhelezy: sostoyanie problemy i sobstvennye nablyudeniy. [Thyroid adenomas: state of the problem and own observations]. Sovremennye aspekty khirurgicheskoi endokrinologii [Modern aspects of surgical endocrinology]. Izhevsk, 2009. рр.91-93. [in Russian] 14 Kozykenova Zh.U., Zhagiparova Zh.K. i dr. Genomnaya nestabil'nost' pri onkotsitarnoi follikulyarnoi adenome shchitovidnoi zhelezy. [Genomic instability in oncocytic follicular adenoma of the thyroid gland]. Astana meditsinalyқ zhurnaly [Astana Medical Journal.] 2017. №3. рр.146-150. [in Kazakh] 15 Kozykenova Zh.U., Zhetpisbaev B.A. i dr. Onkotsitarnyi variant follikulyarnykh opukholei shchitovidnoi zhelezy.Obzor literatury.[Cancer variant of follicular tumors of the thyroid gland] (Literature review). Zhurnal Medicine [Journal of Medicine]. Almaty, 2016. №11 (173). рр. 60-64. [in Kazakhn] 16 Luzhanskaya E.M. Differentsial'naya morfologicheskaya diagnostika follikulyarnoi adenomy shchitovidnoi zhelezy i uzlovogo zob. [Differential morphological diagnosis of follicular adenoma of the thyroid gland and nodular goiter]. Vyatskii meditsinskii vestnik [Vyatka Medical Herald]. 2009. №1. р. 76. [in Russian] 17 Luzhanskaya E.M. Sravnitel'naya morfologicheskaya kharakteristika netoksicheskoi follikulyarnoi adenomy shchitovidnoi zhelezy i adenomatoidnoi giperplazii pri uzlovom zobe. [Comparative morphological characteristics of non-toxic follicular thyroid adenoma and adenomatoid hyperplasia with nodular goiter]. Permskii meditsinskii zhurnal [Perm medical journal]. 2010. №2. рр.97-102. [in Russian] 18 MKB-10:Mezhdunarodnaya statisticheskaya klassifikatsiya boleznei i problem, svyazannykh so zdorov'em:10-i peresmotr. Tom 1: Chast' 2. [ICD-10: International Statistical Classification of Diseases and Related Health Issues: 10th Revision]. Volume 1: Part 2. Р.12. [in Russian] 19 Orlinskaya N.Yu. Dooperatsionnaya morfologicheskaya diagnostika uzlovykh obrazovanii shchitovidnoi zhelezy. (lektsiya). [Preoperative morphological diagnosis of thyroid nodules] (lecture). Meditsinskii al'manakh [Medical Almanac]. 2014. №5(35). pp. 138-141. [in Russian] 20 Orlinskaya N.Yu., Khmel'nitskaya N.M. Patologiya shchitovidnoi zhelezy u zhitelei Nizhegorodskoi oblasti po dannym operatsionnogo materiala. [Pathology of the thyroid gland in residents of the Nizhny Novgorod region according to operational material]. Meditsinskii al'manakh [Medical Almanac]. 2011.№4. pp. 160–161. [in Russian] 21 Pavlova T.V., Pavlov I.A. Kliniko-morfologicheskie aspekty raka shchitovidnoi zhelezy. [Clinical and morphological aspects of thyroid cancer]. Nauchnye vedomosti: Farmatsiya. [Scientific statements: Pharmacy]. 2011. №4. pp. 13–20. [in Russian] 22 Petrov V.G., Nelaeva A.A., Yakimov S. A., Mashkin A. M., Malinin D.I. Follikulyarnaya adenoma shchitovidnoi zhelezy. [Thyroid follicular adenoma]. Sibirskii onkologicheskii zhurnal [Siberian Oncological Journal]. 2006. №1.pp.80-81. [in Russian] 23 Pinskii S.B., Beloborodov V.A. Adenoma shchitovidnoi zhelezy. [Thyroid adenoma]. Sib. med. zhurnal [Sib. honey. magazine]. Irkutsk, 2010. №3.pp.73-77. [in Russian] 24 Timofeeva L.A., Aleshina T. N., Semenov V. D. Analiz vozmozhnykh prichin avtonomnoi adenomy shchitovidnoi zhelezy. [Analysis of the possible causes of autonomous thyroid adenoma]. Vestnik ChGU [Bulletin of ChGU]. 2014. №2. pp. 378-384. [in Russian] 25 Troshina E.A., Yushkov P.V., Mazurina N.V., Egorycheva E.K., Abesadze I.A. Follikulyarnaya neoplaziya shchitovidnoi zhelezy. [Thyroid follicular neoplasia]. Problemy endokrinologii [Problems of endocrinology]. 2006. №1. pp. 22-25. [in Russian] 26 Khmel'nitskii O.K. Tsitologicheskaya i gistologicheskaya diagnostika zabolevanii shchitovidnoi zhelez [Cytological and histological diagnosis of thyroid diseases]. SPb.: SOTIS, 2002. p.288. [in Russian] 27 Chumakov P.M. Belok r53 i ego universal'nye funktsii v mnogokletochnom organizme. [P53 protein and its universal functions in a multicellular organism]. Uspekhi biologicheskoi khimii [Advances in biological chemistry]. 2007. T. 47. pp. 3-52. 28 Churuksaeva O.N., Kolomiets L.A., Savenkova O.V., Nedosekov V.V. Immunogistokhimicheskie faktory v prognoze mestno-rasprostranennogo raka sheiki matki. [Immunohistochemical factors in the prognosis of locally advanced cervical cancer]. Opukholi zhenskoi reproduktivnoi sistemy [Tumors of the female reproductive system]. 2012. №3-4. pp.126-133. [in Russian] 29 Shabalina E.A., Morgunova T.B., Orlova S.V., Fadeev V.V. Selen i shchitovidnaya zheleza. [Selenium and Thyroid]. KET. 2011. №2. pp. 7-18. [in Russian] 30 Shesterikov A.S. Follikulyarnaya neoplaziya shchitovidnoi zhelezy (kliniko-morfologicheskie korrelyatsii, khirurgicheskoe lechenie: avtoref. kand. med. nauk. [Follicular neoplasia of the thyroid gland (clinical and morphological correlations, surgical treatment): Abstract of Candidate of Medical Sciences]. SPb., 2006. pp 27. [in Russian] 31 Baloch Z.W., Fleisher S., LiVolsi V.A. [Diagnosis of «Follicular Neoplasm»: a Gray Zone in Thyroid Fine-needle Aspiration Cytology Diagn]. Cytopathol. 2002. № 26(1). pp.41- 46. 32 Baloch Z.W., LiVolsi V.A. [Follicular-Patterned Lesions of the Thyroid. The Bane of the Pathologist]. Am.J.Clin.Pathol. 2002. №117.pp.143-150. 33 Bronner M., LiVolsi V.A. [Oxyphilic (Askenasy/Hu¨rthle cell) tumors of the thyroid: microscopic features predict biologic behavior]. Surg Pathol. 1988. №1.pp. 137-150. 34 Bondeson L., Azavedo E., Bondeson A.G., Caspersson T., Ljungberg O. [Nuclear DNA content and behavior of oxyphil thyroid tumors]. Cancer. 1986. №58. pp.672-675. 35 Bork P., Hofmann K., Bucher P., Neuwald A.F., Altschul S.F. et al. [A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins]. FASEB J. 1997. №11. pp. 68-76. 36 Caplan R.H., Abellera R.M., Kisken W.A. [Hurthle cell tumors of the thyroid gland: a clinicopathologic review and long-term follow-up]. JAMA. 1984. №251. Р.3114-3117. 37 Difilippantonio M.J., Petersen S., Chen H.T., Johnson R., Jasin M., Kanaar R., Ried T., Nussenzweig A. [Evidence for replicativerepair of DNAdouble-strand breaks leading to oncogen ictrans location and geneamplification]. J Exp Med. 2002. №196.Р.469-480. 38 Fagin F.A., Matsuo K., Karmakar A. еt al. [High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas]. J. Clin. Invest. 1993. Vol. 91, №1. P. 179-184. 39 Grant C.S., Barr D., Goellner J.R. et al. [Benign Hürthle cell tumors of the thyroid: a diagnosis to be trusted?]. World J. Surg. 1988. Vol. 12. P. 488-495. 40 Har-El G., Hadar T., Segal K., Levy R., Sidi J. [Hurthle cell carcinoma of the thyroid gland: a tumor of moderate malignancy]. Cancer. 1986. №57.Р.1613-1617. 41 Harcourt-Webster J.N., Stott N.C. [Histochemical study of oxidative and hydrolyticenzymes in the human thyroid]. J. Pathol Bacteriol. 1966. Vol. 92. P. 291-302. 42 Herrmann M., Baunoch DA., Maliarik M. еt al. [P53 genealterationsi n differentiated thyroid cancers]. Oncol. Rep. 1995. Vol. 2. P. 741-748. 43 Hunt JL., Tometsko M., LiVolsi VA., Swalsky P., Finkelstein SD., Barnes E.L. [Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid]. Am J Surg Pathol. 2003. №27.Р.1559-1564. 44 Ito T., Seyama T., Mizuno T. et al. [Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland]. Cancer Res. 1992. Vol. 52, №5. P. 1369-1371. 45 Joo W.S., Jeffrey P.D., Cantor S.B., Finnin M.S., Livingston D.M. et al. [Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCTstructure]. Genes Dev. 2002. №16.Р. 583-593. 46 Jones S. N., Hancock A. R. et al. [Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis]. Proc Natl Acad Sci. USA, 1998. № 95(26). Р.15608-12. 47 Jossart G.H.,Epstein H.D.,Shaver J.K.et al.[Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines]. J. Clin. Endocrinol. Metab.1996. Vol. 81, №10. P. 3498-3504. 48 Kamb A., Gruis N.A., Weaver Feldhaus J. et al. [A cell regulator potentially involved in genesis of many tumor types]. Science. 1994. Vol. 264, №5157. P. 436-440. 49 Kovalev S., Marchenko N., Swendeman S., LaQuaglia M., Moll U. M. [Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines]. Cell Growth Differ. 1998. №9. Р. 897–903. 50 Lassmann M., Hanscheid H., Gassen D., Biko J., Meineke V. et al. [In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodinetherapy of differentiated thyroid cancer]. J Nucl Med. 2010. №51. Р.1318-1325. 51 Lozano G., Elledge S.J. [p53 sends nucleotides to repair DNA]. Nature. 2000. №404. Р.24-25. 52 Muller P.A., Vousden K.H. [Mutant p53 in cancer: new functions and therapeutic opportunities]. Cancer Cell. 2014. №25.Р. 304-317. 53 Moynahan M.E., Jasin M. [Loss of heterozygosity in duced byachromosomal double-strandbreak]. Proc Natl Acad Sci. USA, 1997. №94.Р.8988-8993. 54 Olive K.P., Politi K. [Translational therapeutics in genetically engineered mouse models of cancer]. Cold Spring Harb Protoc. 2014. №2.Р.131-43 // doi: 10.1101/pdb.top069997. 55 Panier S., Boulton S.J. [Double-strand break repair:53BP1 comes into focus]. Nat Rev Mol Cell Biol. 2014. №15. Р.7-18. 56 Pacini F., Burroni L., Ciuoli C. et al. [Management of thyroid nodules: a clinicopathological, evidence_based approach]. Eur. J. of Nucl. Med. and Molec. Imaging. 2004. Vol. 31. P. 1443–1449. 57 Pipiras E., Coquelle A., Bieth A., Debatisse M. [Interstitial deletions and intrachromosomal amplification initiated from a double-strand break targeted to a mammalian chromosome]. EMBOJ. 1998. №17. Р. 325-33. 58 Rappold I., Iwabuclii K., Date Т., Chen J. [Tumor suppressor p53 binding protein I (53BP1) is involved in DNA damage-signaling pathways]. Journal of Cell Biology. 2001. Vol. 153, №3. P. 613-620. 59 Rinaldo C., Prodosmo A., Mancini F. et al. [MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis]. Mol Cell. 2007. №25. Р.739-50. 60 Richardson C., Jasin M. [Frequent chromosomal translocations induced by DNA double-strand breaks] // Nature. 2000. №405.Р. 697-700. 61 Shimizu H., Hupp T.R. [Intrasteric regulation of MDM2]. Trends Biochem Sci. 2003. № 28(7). Р.346-349. 62 Shmueli A., Oren M. [Mdm2: p53’slifesaver?]. Mol Cell. 2007. №25.Р.794-796. 63 Schultz L.B., Chehab N.H., Malikzay A., Halazonetis T.D. [p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks]. J Cell Biol. 2000. №151.Р.1381-90. 64 Schwab M., Praml C., Amler L.C. [Genes Chromosomes]. Cancer.1996. №16. Р. 211-229. 65 Soares P., Trovisco V., Rocha A.S. et al. [BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC]. Oncogene.2003. №22.Р.4578-4580. 66 Trovisco V., Vieira-Castro I., Soares P. et al. [BRAF mutations are associated with some histological types of papillary thyroid carcinoma]. J Pathol. 2004. №202.Р. 247-251. 67 Ward I.M., Minn K., Jorda K.G., Chen J. [Accumulation of checkpoint protein 53BP1 at DNA breaks in volvesitsbinding to phosphory lated histone H2AX]. J Biol Chem. 2003. №278.Р.19579-82. 68 Ward I.M., Minn K., van Deursen J., Chen J. [p53Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice]. Mol Cell Biol. 2003. №23. Р.2556-2563. 69 Wang H., Zhang X., Teng L., Legerski R.J. [DNA damage checkpoint recovery and cancer development]. Exp Cell Res. 2015. №334. Р. 350-358. 70 Wallace M.D., Southard T.L., Schimenti K.J., Schimenti J.C. Role of DNA damage response pathways in preventingcarcinogenesis caused by intrinsic replication stress. Oncogene. 2014. №33. Р. 3688-3695. 71 Zamzami N., Krotmer G. P53 in apoptosis control: introduction. Biochemical and Biophysical Research Communications. 2005. №331(3). P.685-687. 72 Zhu C., Mills K.D., Ferguson D.O., Lee C., Manis J., Fleming J., Gao Y., Morton C.C., Alt F.W., Banin S., Moyal L., Shieh S., et al. [Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations]. Cell. 2002. №109.Р.811-21. 73 Zedenius J., Larsson C., Wallin G. et al. [Alterations of p53 and expression of WAF1/p21 in human thyroid tumors]. Thyroid. 1996. Vol.6, №1. P. 1-9. 74 Xu Y., Baltimore D. [Dual roles of AT Minthecellular response to radiation and in cell growth control]. Genes Dev. 1996. №10.Р.2401-10. 75 Xu Y., Yang E.M., Brugarolas J., Jacks T., Baltimore D. [Involvement of p53 and p21 in cellular defects and tumorigenesis in Atm2/2 mice]. MolCellBiol.1998. №18. Р.4385-4390.
Number of Views: 333

Key words:

Bibliography link

Козыкенова Ж.У., Жетписбаев Б.А., Нурмадиева Г.Т., Уразалина Н.М., Ибрагимова Л.А. Формирование очагов Р53 связанного белка 1 в опухолях щитовидной железы: активация генетической нестабильности в течении канцерогенеза щитовидной железы. Обзор литературы // Наука и Здравоохранение. 2019. 2 (Т.21). С. 25-37. Коzykenova Zh.U., Zhetpisbaev B.А., Nurmadieva G.Т., Urazalina N.М., Ibraqimova L.А. Formation of foci of P53 bound protein 1 in thyroid tumors: activation of genetic instability during thyroid carcinogenesis. Literature review. Nauka i Zdravookhranenie [Science & Healthcare]. 2019, (Vol.21) 2, pp. 25-37. Козыкенова Ж.У., Жетписбаев Б.А., Нурмадиева Г.Т., Уразалина Н.М., Ибрагимова Л.А. Қалқанша безі ісіктерінде р53-байланыстырушы нәруыз 1 ошақтарының қалыптасуы: қалқанша безі канцерогенезінде геномды тұрақсыздықтың белсенділігі. Әдебиеттерді шолу // Ғылым және Денсаулық сақтау. 2019. 2 (Т.21). Б. 25-37.

Авторизируйтесь для отправки комментариев